Cargando…

Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients

Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atheroscler...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuciuc, Valeri, Tshori, Sagi, Grib, Livi, Sella, Gal, Tuvali, Ortal, Volodarsky, Igor, Welt, Michael, Fassler, Michael, Shimoni, Sara, George, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656572/
https://www.ncbi.nlm.nih.gov/pubmed/36361908
http://dx.doi.org/10.3390/ijms232113121
_version_ 1784829469076226048
author Cuciuc, Valeri
Tshori, Sagi
Grib, Livi
Sella, Gal
Tuvali, Ortal
Volodarsky, Igor
Welt, Michael
Fassler, Michael
Shimoni, Sara
George, Jacob
author_facet Cuciuc, Valeri
Tshori, Sagi
Grib, Livi
Sella, Gal
Tuvali, Ortal
Volodarsky, Igor
Welt, Michael
Fassler, Michael
Shimoni, Sara
George, Jacob
author_sort Cuciuc, Valeri
collection PubMed
description Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atherosclerotic macrophages. We hypothesized that sTREM2 would predict cardiovascular mortality in patients with established coronary atherosclerosis (CAD). Consecutive patients undergoing coronary angiography with the establishment of the diagnosis of CAD (n = 230) and without CAD (n = 53) were tested for their baseline serum sTREM2 levels. All patients were followed up for 84 months or until death occurred. sTREM2 correlated with age; however, no association was found between sTREM2 and the number of atherosclerotic vessels involved (p = 0.642). After 84 months of follow-up, 68 out of the 230 CAD patients had died. After adjusting for age and other risk factors, the adjusted hazard ratio for the highest quartile of sTREM2 was 2.37 (95% confidence interval 1.17–4.83) for death. In patients with established CAD, serum sTREM2 appears to predict cardiovascular death as a potential surrogate for plaque rupture. TREM2 and its soluble extracellular form might be implicated in the fate of the atherosclerotic plaque, but corroboration within larger studies is needed.
format Online
Article
Text
id pubmed-9656572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96565722022-11-15 Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients Cuciuc, Valeri Tshori, Sagi Grib, Livi Sella, Gal Tuvali, Ortal Volodarsky, Igor Welt, Michael Fassler, Michael Shimoni, Sara George, Jacob Int J Mol Sci Article Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atherosclerotic macrophages. We hypothesized that sTREM2 would predict cardiovascular mortality in patients with established coronary atherosclerosis (CAD). Consecutive patients undergoing coronary angiography with the establishment of the diagnosis of CAD (n = 230) and without CAD (n = 53) were tested for their baseline serum sTREM2 levels. All patients were followed up for 84 months or until death occurred. sTREM2 correlated with age; however, no association was found between sTREM2 and the number of atherosclerotic vessels involved (p = 0.642). After 84 months of follow-up, 68 out of the 230 CAD patients had died. After adjusting for age and other risk factors, the adjusted hazard ratio for the highest quartile of sTREM2 was 2.37 (95% confidence interval 1.17–4.83) for death. In patients with established CAD, serum sTREM2 appears to predict cardiovascular death as a potential surrogate for plaque rupture. TREM2 and its soluble extracellular form might be implicated in the fate of the atherosclerotic plaque, but corroboration within larger studies is needed. MDPI 2022-10-28 /pmc/articles/PMC9656572/ /pubmed/36361908 http://dx.doi.org/10.3390/ijms232113121 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cuciuc, Valeri
Tshori, Sagi
Grib, Livi
Sella, Gal
Tuvali, Ortal
Volodarsky, Igor
Welt, Michael
Fassler, Michael
Shimoni, Sara
George, Jacob
Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title_full Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title_fullStr Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title_full_unstemmed Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title_short Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
title_sort circulating soluble trem2 and cardiovascular outcome in cohort study of coronary atherosclerosis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656572/
https://www.ncbi.nlm.nih.gov/pubmed/36361908
http://dx.doi.org/10.3390/ijms232113121
work_keys_str_mv AT cuciucvaleri circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT tshorisagi circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT griblivi circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT sellagal circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT tuvaliortal circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT volodarskyigor circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT weltmichael circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT fasslermichael circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT shimonisara circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients
AT georgejacob circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients